Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multi-Center, Dose-Escalation Study, to Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta in OPMD Patients

Next Previous
X
Search
Trial Profile

Multi-Center, Dose-Escalation Study, to Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta in OPMD Patients

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trehalose (Primary)
  • Indications Oculopharyngeal muscular dystrophy
  • Focus Adverse reactions
  • Acronyms HOPEMD
  • Sponsors Bioblast Pharma

    • Most Recent Events

    • 26 Sep 2016 According to a Bioblast Pharma media release, results from this study including an extension study (Profile 700252783) are being presented at the annual scientific meeting of the Muscle Study Group Society (MSGS).
    • 25 May 2016 According to Bioblast Pharma media release, the company announced positive final results from the HOPEMD trial and presented final study results at Myology 2016 and the American Academy of Neurology (AAN) 2016 Annual Meeting.
    • 21 Apr 2016 Preliminary results of 24 weeks presented at the 68th Annual Meeting of the American Academy of Neurology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top